10x Genomics, INC Form 4 insider transactions

John R Stuelpnagel, a Director of 10x Genomics, Inc., sold 20,000 shares of common stock on August 11, 2026.

Serge Saxonov, CEO of 10x Genomics, has reported the sale of Class A Common Stock valued at over $25 million through a pre-arranged trading plan.

10x Genomics Director Shehnaaz Suliman reported the sale of Class A Common Stock under a pre-arranged trading plan.

Director Sarah Teichmann was granted 8,829 restricted stock units in 10x Genomics, Inc. as part of standard equity compensation.

Director Shehnaaz Suliman was granted 8,829 restricted stock units as part of her compensation package with 10x Genomics.

Director John R. Stuelpnagel was granted 8,829 restricted stock units as part of his compensation package with 10x Genomics.

Director Kimberly J. Popovits was granted 8,829 restricted stock units as part of her compensation package with 10x Genomics.

Director Alan Mateo was granted 8,829 restricted stock units by 10x Genomics, Inc. as part of his compensation.

Director Sridhar Kosaraju was granted 8,829 restricted stock units by 10x Genomics, Inc. as part of his ongoing service.

CEO Serge Saxonov sold 28,893 shares of 10x Genomics stock to cover tax obligations and via a pre-arranged trading plan.

President and Chief Scientific Officer Benjamin J. Hindson sold 11,595 shares of 10x Genomics to cover tax withholding requirements.

10x Genomics CFO Adam Taich sold 15,098 shares of Class A Common Stock to satisfy tax withholding obligations related to RSU vesting.

CEO Serge Saxonov sold 5,000 shares of 10x Genomics Class A Common Stock via a pre-arranged Rule 10b5-1 trading plan.

10x Genomics CEO Serge Saxonov sold 15,000 shares of Class A Common Stock for approximately $289,000 through a pre-arranged 10b5-1 trading plan.

10x Genomics CEO Serge Saxonov reported sales of Class A Common Stock totaling 16,152 shares and a gift of 2,750 shares under a pre-arranged 10b5-1 trading plan.

10x Genomics CEO Serge Saxonov was granted 157,895 restricted stock units, aligning his interests with long-term shareholder value.

10x Genomics, Inc. awarded 88,816 restricted stock units to Benjamin J. Hindson, President and Chief Scientific Officer, as part of his compensation.

10x Genomics' Chief Financial Officer, Adam Taich, was granted 106,579 Restricted Stock Units, signaling long-term executive alignment.

10x Genomics Director Sarah A. Teichmann sold 7,579 shares of Class A Common Stock at $19.41 per share under a pre-arranged Rule 10b5-1 trading plan.

10x Genomics CEO Serge Saxonov sold 9,632 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

10x Genomics Chief Financial Officer Adam Taich sold 8,968 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

10x Genomics President and Chief Scientific Officer, Benjamin J. Hindson, sold 7,826 shares of Class A Common Stock to cover tax withholding obligations.

10x Genomics CEO Serge Saxonov exercised stock options to acquire 50,000 shares of Class A Common Stock at $1.20 per share, increasing his direct beneficial ownership.

10x Genomics' Chief Financial Officer, Adam Taich, sold 11,888 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold 8,283 shares of Class A Common Stock to cover tax withholding obligations.

10x Genomics CEO Serge Saxonov sold 13,261 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

10x Genomics CEO Serge Saxonov reported a gift of 900 Class A Common Stock shares and detailed various beneficial ownership holdings.

10x Genomics CEO Serge Saxonov sold 9,348 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

10x Genomics' Chief Financial Officer, Adam Taich, sold 22,315 shares of Class A Common Stock on August 22, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold 7,486 shares of Class A Common Stock to cover tax withholding obligations.